As one of the larger segments in the overall market for acute pain therapies, the treatment of postoperative pain has experienced substantial growth over the past decade due to the market uptake of Mallinckrodt Pharmaceuticals’ Ofirmev and Pacira Pharmaceuticals’ Exparel in the United States. Nevertheless, unmet need remains for potent postoperative pain therapies that are not opioid analgesics and that can stave off persistent pain. Emerging therapies for moderate to severe postoperative pain will have to demonstrate convincing efficacy, safety, and convenience in multiple, well-designed clinical trials and have these advantages translate into clinical practice. Given generic analgesics’ low price, wide availability, and entrenched position in the first-line treatment of postoperative pain, market access will be challenging for emerging postoperative pain therapies unless a strong value proposition is made.
- What are the treatment drivers and goals for moderate to severe postoperative pain?
- What drug attributes are key influences, which have limited impact, and which are hidden opportunities?
- How do current therapies perform on key treatment drivers and goals for moderate to severe postoperative pain?
- What are the prevailing areas of unmet need and opportunity in moderate to severe postoperative pain?
- What trade-offs across different clinical attributes and prices are acceptable to U.S. and European anesthesiologists for a hypothetical new moderate to severe postoperative pain drug?
Provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.
Markets covered: United States, United Kingdom, France, Germany
Primary research: Survey of 60 U.S. and 31 European anesthesiologists
Key companies: Mallinckrodt Pharmaceuticals, Pacira Pharmaceuticals, Trevena, Heron Therapeutics
Key drugs: Oral opioids, morphine IV, ketorolac IV/IM, Ofirmev, Perfalgan, tramadol, Exparel, bupivacaine, oliceridine, HTX-011
Key metrics included:
- Stated versus derived analysis of U.S. and European physicians’ prescribing behavior.
- Conjoint analysis with U.S. and European physicians, including market simulator.
- Assessment of current drug performance against treatment drivers and goals.
- Physician perceptions of unmet need in disease/subpopulation covered and related diseases/subpopulations.
- Analysis of remaining drug development opportunities.